Hospital
Danville Regional Medical Center, LLC
Danville Regional Medical Center, LLC was paid $65.11M by Medicaid between Jan 2018 and Dec 2024, across 491 billing codes. Its largest line is 99284, emergency room visit (serious) — 13% of everything it billed.
33Billing provider infoDANVILLE REGIONAL MEDICAL CENTER, LLC
DANVILLE, VA 24541
DANVILLE, VA 24541
33aNPI1154419737assigned 10/10/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$65.11M
24GClaims2,330,689
24DCodes billed491
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Virginia
Rank by total paid#9 of 80
Median peer was paid$14.69M
This provider vs. median4.4×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official LAWRENCE, CHARLOTTE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 344,140 | $4.68M | |
| 2019 | 381,655 | $6.24M | |
| 2020 | 276,584 | $7.80M | |
| 2021 | 293,878 | $8.13M | |
| 2022 | 281,415 | $8.02M | |
| 2023 | 423,788 | $16.07M | |
| 2024incomplete | 329,229 | $14.18M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 13% | 65,401 | 52,176 | $8.57M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 13% | 61,944 | 52,259 | $8.33M |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 35,437 | 25,175 | $8.20M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.7% | 36,756 | 28,851 | $4.34M |
| 70450 | Computed tomography, head or brain; without contrast material | 4.1% | 20,400 | 16,866 | $2.68M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.0% | 18,485 | 16,543 | $2.62M |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 3.5% | 25,851 | 14,653 | $2.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.7% | 11,130 | 9,577 | $1.77M |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 23,636 | 20,897 | $1.49M |
| G0378 | Hospital observation service, per hour | 2.1% | 9,920 | 7,348 | $1.39M |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 2.1% | 10,448 | 6,605 | $1.35M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.0% | 8,736 | 7,397 | $1.30M |
479 more codes
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 8,404 | $1.29M |
| 71275 | Computed tomographic angiography, chest, with contrast material | 1.1% | 4,364 | $718K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 1.0% | 7,731 | $679K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,042 | $616K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 3,052 | $612K |
| 80053 | Comprehensive metabolic panel | <1% | 138,245 | $571K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 1,457 | $558K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 272 | $551K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 24,702 | $535K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 12,945 | $512K |
| 36475 | <1% | 388 | $511K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 20,360 | $440K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 3,071 | $407K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 2,658 | $402K |
| 96367 | <1% | 6,379 | $351K | |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 336 | $315K |
| 93970 | <1% | 3,315 | $288K | |
| 93971 | <1% | 3,730 | $281K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 9,115 | $275K |
| 78815 | Positron emission tomography (PET) for limited area imaging | <1% | 385 | $270K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 155,279 | $261K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 15,939 | $255K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 3,311 | $254K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 4,869 | $250K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 37,364 | $240K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 8,848 | $225K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 687 | $219K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 1,961 | $210K |
| 36430 | <1% | 2,665 | $203K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 396 | $195K |
| 10060 | <1% | 1,436 | $181K | |
| 76830 | Ultrasound, transvaginal | <1% | 2,081 | $179K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,145 | $168K |
| 80050 | General health panel | <1% | 2,968 | $165K |
| 80061 | Lipid panel | <1% | 23,949 | $164K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 31,729 | $164K |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | <1% | 214 | $161K |
| 12001 | <1% | 813 | $159K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 805 | $153K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 2,513 | $148K |
| 47562 | <1% | 52 | $146K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 19,362 | $145K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,160 | $135K |
| 97161 | <1% | 2,777 | $132K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 7,245 | $131K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 6,767 | $121K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 259 | $120K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 2,518 | $110K |
| 93017 | <1% | 1,559 | $108K | |
| 83880 | <1% | 18,813 | $108K | |
| 82607 | <1% | 10,525 | $107K | |
| 76770 | <1% | 1,134 | $107K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 47,803 | $104K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 26,159 | $103K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,799 | $93K |
| 76801 | <1% | 2,036 | $91K | |
| 11043 | <1% | 535 | $91K | |
| 71250 | <1% | 2,187 | $91K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 26,583 | $90K |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 377 | $86K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 904 | $82K |
| J9271 | Injection, pembrolizumab, 1 mg | <1% | 16 | $80K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 27,544 | $79K |
| 71045 | Radiologic examination, chest; single view | <1% | 52,899 | $77K |
| 77412 | <1% | 243 | $77K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,337 | $73K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,890 | $72K |
| 77336 | <1% | 922 | $71K | |
| 87040 | <1% | 22,236 | $68K | |
| 86235 | <1% | 979 | $68K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 6,567 | $67K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 781 | $66K |
| 70496 | <1% | 355 | $65K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 3,678 | $63K |
| 84439 | <1% | 10,380 | $63K | |
| 72131 | <1% | 967 | $60K | |
| 76642 | <1% | 629 | $60K | |
| 12002 | <1% | 349 | $59K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 66,410 | $57K |
| 82728 | <1% | 7,601 | $56K | |
| 29125 | <1% | 1,015 | $53K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 6,555 | $49K |
| 87081 | <1% | 11,321 | $48K | |
| 97165 | <1% | 1,041 | $48K | |
| 72100 | <1% | 3,810 | $47K | |
| 84145 | <1% | 11,218 | $47K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 42,586 | $47K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 4,035 | $46K |
| 70491 | <1% | 255 | $46K | |
| 86703 | <1% | 3,228 | $46K | |
| 76536 | <1% | 509 | $46K | |
| 70486 | <1% | 1,648 | $46K | |
| 86003 | <1% | 1,018 | $45K | |
| 71271 | <1% | 513 | $44K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 203 | $44K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 18,810 | $43K |
| 12011 | <1% | 229 | $42K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 180 | $42K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 620 | $40K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | <1% | 2,061 | $38K |
| 93975 | <1% | 456 | $38K | |
| 85652 | <1% | 7,074 | $37K | |
| 90715 | <1% | 2,769 | $37K | |
| 74018 | <1% | 3,975 | $36K | |
| 82247 | <1% | 3,293 | $36K | |
| 82746 | <1% | 6,026 | $34K | |
| 83540 | <1% | 9,034 | $33K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 214 | $33K |
| 93880 | <1% | 547 | $31K | |
| 81001 | <1% | 62,491 | $31K | |
| 96415 | <1% | 159 | $30K | |
| 84466 | <1% | 4,564 | $30K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 7,509 | $30K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 254 | $29K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,606 | $29K |
| 97116 | <1% | 1,750 | $29K | |
| 84702 | <1% | 10,128 | $28K | |
| 84484 | <1% | 40,275 | $28K | |
| 87077 | <1% | 9,075 | $28K | |
| 97162 | <1% | 371 | $28K | |
| 88342 | <1% | 2,752 | $27K | |
| 86803 | <1% | 2,013 | $26K | |
| 85027 | <1% | 12,335 | $26K | |
| 83735 | <1% | 26,974 | $25K | |
| 73030 | <1% | 3,467 | $25K | |
| 85379 | <1% | 6,323 | $25K | |
| 70498 | <1% | 367 | $24K | |
| 80055 | <1% | 447 | $24K | |
| 73630 | <1% | 3,448 | $23K | |
| 43248 | <1% | 46 | $23K | |
| 29515 | <1% | 487 | $23K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 626 | $22K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,460 | $22K |
| 73610 | <1% | 3,110 | $22K | |
| 73130 | <1% | 2,966 | $22K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,434 | $20K |
| 82553 | <1% | 13,017 | $20K | |
| 82962 | <1% | 31,368 | $20K | |
| 72141 | <1% | 103 | $20K | |
| 31500 | <1% | 83 | $20K | |
| 76870 | <1% | 228 | $20K | |
| 43235 | <1% | 40 | $19K | |
| 96376 | <1% | 10,334 | $19K | |
| 93976 | <1% | 363 | $19K | |
| 73560 | <1% | 3,894 | $19K | |
| 82570 | <1% | 5,871 | $19K | |
| 93798 | <1% | 146 | $16K | |
| 87186 | <1% | 8,897 | $16K | |
| J1815 | Injection, insulin, per 5 units | <1% | 6,061 | $16K |
| 83690 | <1% | 28,722 | $16K | |
| 87503 | <1% | 3,969 | $16K | |
| 82043 | <1% | 5,157 | $15K | |
| 86900 | <1% | 7,171 | $15K | |
| 77334 | <1% | 108 | $15K | |
| 80074 | <1% | 1,111 | $14K | |
| 86140 | <1% | 3,575 | $14K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,842 | $14K |
| 87070 | <1% | 3,726 | $14K | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 1,188 | $14K |
| 86780 | <1% | 2,213 | $14K | |
| 73502 | <1% | 2,400 | $14K | |
| 80076 | <1% | 2,236 | $13K | |
| 88360 | <1% | 836 | $13K | |
| 97602 | <1% | 184 | $13K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 949 | $13K |
| 96368 | <1% | 2,104 | $13K | |
| 51702 | <1% | 1,267 | $13K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 14,256 | $13K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 305 | $12K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 4,281 | $12K |
| 85610 | <1% | 37,609 | $12K | |
| 86225 | <1% | 927 | $12K | |
| 88185 | <1% | 197 | $11K | |
| 83605 | <1% | 19,509 | $11K | |
| 81025 | <1% | 14,129 | $11K | |
| 84550 | <1% | 5,088 | $11K | |
| 97597 | <1% | 235 | $11K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 29 | $10K |
| 83516 | <1% | 778 | $10K | |
| 82677 | <1% | 179 | $10K | |
| J2704 | Injection, propofol, 10 mg | <1% | 11,907 | $9K |
| 83655 | <1% | 912 | $9K | |
| 81000 | <1% | 4,235 | $9K | |
| 73110 | <1% | 1,580 | $9K | |
| 87147 | <1% | 1,595 | $9K | |
| 82784 | <1% | 1,365 | $8K | |
| 36600 | <1% | 12,398 | $8K | |
| 59025 | Fetal non-stress test | <1% | 62 | $8K |
| 83550 | <1% | 2,479 | $8K | |
| 82977 | <1% | 1,186 | $8K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 76 | $8K |
| 87210 | <1% | 4,652 | $8K | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 37 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,843 | $7K |
| 83615 | <1% | 3,514 | $7K | |
| 77065 | Tomosynthesis, mammo | <1% | 178 | $7K |
| 80047 | <1% | 3,294 | $7K | |
| 73080 | <1% | 1,021 | $7K | |
| 94726 | <1% | 83 | $7K | |
| 84112 | <1% | 316 | $7K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 121 | $6K |
| 72040 | <1% | 261 | $6K | |
| 82550 | <1% | 25,348 | $6K | |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 172 | $6K |
| 77066 | Tomosynthesis, mammo | <1% | 218 | $6K |
| 84153 | <1% | 787 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 2,184 | $6K |
| 29581 | <1% | 177 | $6K | |
| 92950 | <1% | 15 | $6K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 604 | $6K |
| 87340 | <1% | 953 | $5K | |
| 73590 | <1% | 1,389 | $5K | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 45 | $5K |
| 86850 | <1% | 6,221 | $5K | |
| 73562 | <1% | 497 | $5K | |
| 96402 | <1% | 63 | $5K | |
| 85730 | <1% | 25,976 | $5K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 1,796 | $5K |
| 64400 | <1% | 16 | $5K | |
| 77280 | <1% | 21 | $5K | |
| P9612 | Catheterization for collection of specimen, single patient, all places of service | <1% | 1,821 | $5K |
| 88304 | <1% | 1,885 | $5K | |
| 84481 | <1% | 554 | $5K | |
| 82248 | <1% | 1,019 | $5K | |
| 87150 | <1% | 524 | $4K | |
| 83525 | <1% | 565 | $4K | |
| 84165 | <1% | 1,080 | $4K | |
| 82785 | <1% | 492 | $4K | |
| 72050 | <1% | 364 | $4K | |
| 86920 | <1% | 3,090 | $4K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,261 | $4K |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 7,639 | $4K |
| 84100 | <1% | 7,278 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 29,733 | $4K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 15 | $4K |
| 80164 | <1% | 1,032 | $3K | |
| 80177 | <1% | 498 | $3K | |
| 74230 | <1% | 96 | $3K | |
| 86901 | <1% | 7,171 | $3K | |
| 97016 | <1% | 209 | $3K | |
| 86431 | <1% | 436 | $3K | |
| 78306 | <1% | 12 | $3K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 34 | $3K |
| 83883 | <1% | 381 | $3K | |
| 70487 | <1% | 16 | $3K | |
| 94010 | <1% | 88 | $3K | |
| 86038 | <1% | 337 | $3K | |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 212 | $3K |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | <1% | 16 | $3K |
| 73090 | <1% | 667 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 20 | $3K |
| 84703 | <1% | 3,419 | $3K | |
| 88184 | <1% | 194 | $3K | |
| 95816 | <1% | 17 | $3K | |
| 82805 | <1% | 12,839 | $3K | |
| 73564 | <1% | 117 | $3K | |
| 10061 | <1% | 14 | $3K | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 3,302 | $2K |
| 73140 | <1% | 193 | $2K | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 7,817 | $2K |
| 86300 | <1% | 319 | $2K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 156 | $2K |
| 83704 | <1% | 502 | $2K | |
| 82565 | <1% | 1,086 | $2K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 14,295 | $2K |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | <1% | 14 | $2K |
| 86008 | <1% | 362 | $2K | |
| 87507 | <1% | 27 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 241 | $2K |
| 86706 | <1% | 210 | $2K | |
| 82140 | <1% | 3,964 | $2K | |
| 84630 | <1% | 360 | $2K | |
| 86618 | <1% | 269 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 722 | $2K |
| 83021 | <1% | 475 | $2K | |
| 87581 | <1% | 34 | $2K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 13,573 | $2K |
| 74022 | <1% | 909 | $2K | |
| 87536 | <1% | 15 | $2K | |
| 76818 | <1% | 17 | $1K | |
| 72070 | <1% | 77 | $1K | |
| J0561 | Injection, penicillin g benzathine, 100,000 units | <1% | 60 | $1K |
| C1776 | Joint device (implantable) | <1% | 17 | $1K |
| 82947 | <1% | 326 | $1K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 114 | $1K |
| 85045 | <1% | 704 | $1K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 321 | $1K |
| 94150 | <1% | 88 | $1K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 18,585 | $1K |
| 86757 | <1% | 122 | $1K | |
| 84403 | <1% | 141 | $1K | |
| 0011A | <1% | 66 | $1K | |
| 94729 | <1% | 85 | $1K | |
| 87205 | <1% | 1,394 | $1K | |
| 77300 | <1% | 19 | $1K | |
| 74019 | <1% | 106 | $1K | |
| V2632 | Posterior chamber intraocular lens | <1% | 214 | $1K |
| 84207 | <1% | 218 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 12,975 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 1,760 | $1K |
| 87088 | <1% | 735 | $1K | |
| 77080 | <1% | 31 | $1K | |
| 0012A | <1% | 50 | $1K | |
| 73060 | <1% | 178 | $1K | |
| 76981 | <1% | 27 | $1K | |
| 87899 | <1% | 54 | $989.64 | |
| 81003 | <1% | 6,930 | $976.89 | |
| 82105 | <1% | 276 | $917.32 | |
| 72192 | <1% | 16 | $909.13 | |
| 0001A | <1% | 43 | $853.55 | |
| 90686 | <1% | 88 | $817.56 | |
| 86336 | <1% | 179 | $792.28 | |
| 86141 | <1% | 97 | $788.32 | |
| 43760 | <1% | 45 | $779.15 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 4,055 | $767.16 |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 34 | $752.37 |
| 94644 | <1% | 377 | $742.90 | |
| 0002A | <1% | 29 | $737.36 | |
| 88341 | <1% | 76 | $736.57 | |
| 73700 | <1% | 14 | $734.58 | |
| 84425 | <1% | 157 | $721.82 | |
| 87807 | <1% | 772 | $693.18 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 9,881 | $692.57 |
| 86592 | <1% | 73 | $692.27 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 8,685 | $691.09 |
| 73552 | <1% | 204 | $688.37 | |
| G0008 | Administration of influenza virus vaccine | <1% | 121 | $678.88 |
| 92611 | <1% | 64 | $673.64 | |
| 86704 | <1% | 53 | $670.93 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 5,739 | $667.62 |
| 86677 | <1% | 12 | $661.90 | |
| 87486 | <1% | 34 | $643.79 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 652 | $637.50 |
| 80069 | <1% | 324 | $628.09 | |
| 82950 | <1% | 382 | $619.73 | |
| 86787 | <1% | 112 | $605.93 | |
| 96523 | <1% | 46 | $561.70 | |
| 82274 | <1% | 510 | $557.94 | |
| 82180 | <1% | 127 | $545.97 | |
| 96417 | <1% | 669 | $530.72 | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 562 | $524.61 |
| 72170 | <1% | 508 | $520.26 | |
| 82378 | <1% | 200 | $497.60 | |
| 82150 | <1% | 180 | $482.46 | |
| 92526 | <1% | 25 | $476.96 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 8,404 | $469.87 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 26 | $469.70 |
| 83521 | <1% | 204 | $464.41 | |
| 82172 | <1% | 29 | $458.51 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 28 | $457.29 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,932 | $448.80 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 6,408 | $443.86 |
| 72128 | <1% | 31 | $438.48 | |
| 71101 | <1% | 58 | $425.91 | |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 1,973 | $425.77 |
| 92610 | <1% | 14 | $395.29 | |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | <1% | 1,503 | $393.90 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 614 | $385.54 |
| 87102 | <1% | 83 | $382.86 | |
| 86696 | <1% | 27 | $367.55 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,913 | $365.43 |
| J2404 | Injection, nicardipine, 0.1 mg | <1% | 18 | $355.67 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 2,608 | $350.40 |
| J3490 | Unclassified drugs | <1% | 408 | $335.44 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 6,614 | $315.00 |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 836 | $299.67 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 5,833 | $293.30 |
| 84132 | <1% | 613 | $270.82 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 4,298 | $256.82 |
| 84436 | <1% | 21 | $253.27 | |
| 86308 | <1% | 29 | $250.84 | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 413 | $245.12 |
| J0153 | Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) | <1% | 148 | $240.86 |
| 86695 | <1% | 29 | $239.88 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,439 | $237.16 |
| 87522 | Neg quan hep c or qual rna | <1% | 33 | $230.99 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 2,004 | $226.16 |
| 83001 | <1% | 28 | $220.06 | |
| 86334 | <1% | 81 | $214.96 | |
| 87101 | <1% | 26 | $214.55 | |
| 84155 | <1% | 123 | $212.96 | |
| 82010 | <1% | 1,512 | $198.95 | |
| J1953 | Injection, levetiracetam, 10 mg | <1% | 1,302 | $193.91 |
| 70360 | <1% | 12 | $177.91 | |
| 87045 | <1% | 44 | $170.80 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 1,976 | $170.20 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 205 | $164.27 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 3,731 | $148.13 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 2,282 | $140.51 |
| 84146 | <1% | 18 | $136.69 | |
| 84479 | <1% | 12 | $131.98 | |
| 84156 | <1% | 77 | $130.80 | |
| 87075 | <1% | 176 | $122.87 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 3,574 | $122.87 |
| 82525 | <1% | 16 | $117.82 | |
| 87046 | <1% | 45 | $117.03 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 2,954 | $114.88 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 2,377 | $112.85 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 1,227 | $103.95 |
| C1758 | Catheter, ureteral | <1% | 1,831 | $100.37 |
| 91301 | <1% | 12 | $95.36 | |
| 84402 | <1% | 13 | $91.40 | |
| 83695 | <1% | 37 | $90.67 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 32 | $90.00 |
| 80178 | <1% | 48 | $88.21 | |
| 87015 | <1% | 32 | $88.18 | |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 367 | $83.84 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 446 | $77.57 |
| 72072 | <1% | 15 | $71.87 | |
| J1790 | Injection, droperidol, up to 5 mg | <1% | 1,247 | $66.83 |
| 36416 | <1% | 71 | $64.82 | |
| 88112 | <1% | 18 | $60.70 | |
| 99152 | <1% | 118 | $55.34 | |
| 84480 | <1% | 46 | $55.07 | |
| 84154 | <1% | 18 | $52.96 | |
| 88307 | <1% | 45 | $49.72 | |
| 82077 | <1% | 865 | $48.12 | |
| 84295 | <1% | 26 | $41.61 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 807 | $40.33 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 1,251 | $39.81 |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 505 | $38.80 |
| 84450 | <1% | 42 | $29.88 | |
| J7342 | Instillation, ciprofloxacin otic suspension, 6 mg | <1% | 39 | $28.28 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 203 | $27.27 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 834 | $25.73 |
| 88313 | <1% | 17 | $23.16 | |
| 80185 | <1% | 16 | $19.72 | |
| A9270 | Non-covered item or service | <1% | 16,852 | $19.17 |
| J0456 | Injection, azithromycin, 500 mg | <1% | 685 | $13.73 |
| 87428 | <1% | 181 | $13.14 | |
| 87493 | <1% | 39 | $13.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 262 | $12.91 |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 228 | $11.97 |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 35 | $8.94 |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 179 | $8.72 |
| 89051 | <1% | 13 | $6.02 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 22 | $2.40 |
| J0610 | Injection, calcium gluconate (fresenius kabi), per 10 ml | <1% | 27 | $0.43 |
| J0461 | Injection, atropine sulfate, 0.01 mg | <1% | 24 | $0.21 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 461 | $0.00 |
| J3372 | Injection, vancomycin hcl (xellia), not therapeutically equivalent to j3370, 500 mg | 0% | 551 | $0.00 |
| J0736 | Injection, clindamycin phosphate, 300 mg | 0% | 166 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 69 | $0.00 |
| 80179 | 0% | 208 | $0.00 | |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | 0% | 374 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 341 | $0.00 |
| G8997 | Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 83 | $0.00 |
| 80143 | 0% | 197 | $0.00 | |
| C1760 | Closure device, vascular (implantable/insertable) | 0% | 51 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 736 | $0.00 |
| G8996 | Swallowing functional limitation, current status at therapy episode outset and at reporting intervals | 0% | 83 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 60 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 2,229 | $0.00 |
| J3486 | Injection, ziprasidone mesylate, 10 mg | 0% | 276 | $0.00 |
| 70250 | 0% | 12 | $0.00 | |
| A9576 | Injection, gadoteridol, (prohance multipack), per ml | 0% | 137 | $0.00 |
| J0692 | Injection, cefepime hydrochloride, 500 mg | 0% | 35 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 38 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 19 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 421 | $0.00 |
| C1769 | Guide wire | 0% | 1,577 | $0.00 |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 452 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 73 | $0.00 |
| A9585 | Injection, gadobutrol, 0.1 ml | 0% | 69 | $0.00 |
| C1888 | Catheter, ablation, non-cardiac, endovascular (implantable) | 0% | 210 | $0.00 |
| G8998 | Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 46 | $0.00 |
| A9503 | Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries | 0% | 58 | $0.00 |
| 82803 | 0% | 215 | $0.00 | |
| G8980 | Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting | 0% | 42 | $0.00 |
| C1781 | Mesh (implantable) | 0% | 31 | $0.00 |
| 88311 | 0% | 49 | $0.00 | |
| C1892 | Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away | 0% | 43 | $0.00 |
| J9045 | Injection, carboplatin, 50 mg | 0% | 24 | $0.00 |
| J0613 | Injection, calcium gluconate (wg critical care), not therapeutically equivalent to j0612, 10 mg | 0% | 30 | $0.00 |
| J1836 | Injection, metronidazole, 10 mg | 0% | 33 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 17 | $0.00 |
| J0687 | Injection, cefazolin sodium (wg critical care), not therapeutically equivalent to j0690, 500 mg | 0% | 13 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 14 | $0.00 |
| 94660 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLAWRENCE, CHARLOTTE (SECRETARY)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.